Home Home Home Inbox Home Search

Event

Demographics, Clinical Characteristics, and Response to Benralizumab Treatment for Patients with Severe, Eosinophilic Asthma and Fixed Airflow Obstruction [Board No. 411]

Location: Board no. 411
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Sunday
May
20
2:15 PM
4:15 PM

Speaker(s)/Author(s)

Frank Trudo

MD, MBA
AstraZeneca

Marianna Alacqua

PhD
AstraZeneca

Ian Hirsch

PhD
AstraZeneca

James G. Zangrilli

MD
AstraZeneca

Bradley E. Chipps

MD
Capital Allergy and Respiratory Disease Center

View Abstract

Demographics, Clinical Characteristics, and Response to Benralizumab Treatment for Patients with Severe, Eosinophilic Asthma and Fixed Airflow Obstruction

Parent Sessions

  • A101 - MECHANISMS AND CLINICAL FEATURES OF SEVERE ASTHMA...
    05-20-2018 2:15 PM - 4:15 PM
    • Home Home Home Inbox Home Search